ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1
Future Oncology | April 6, 2020 | Volume: 16 | Issue: 15 | Pages: 991-999
10.2217/fon-2020-0176
| PMID 32250167